Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions

被引:53
|
作者
Whitby, Denise [1 ]
Marshall, Vickie A.
Bagni, Rachel K.
Miley, Wendell J.
McCloud, Thomas G.
Hines-Boykin, Rebecca
Goedert, James J.
Conde, Betty A.
Nagashima, Kunio
Mikovits, Judy
Dittmer, Dirk P.
Newman, David J.
机构
[1] NCI Frederick, SAIC Frederick, Viral Epidemiol Sect, AIDS Vaccine Program, Frederick, MD 21702 USA
[2] NCI Frederick, SAIC Frederick, Nat Prod Support Grp, Frederick, MD 21702 USA
[3] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA
[4] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[5] NCI Frederick, SAIC Frederick, Image Anal Lab, Res Technol Program, Frederick, MD 21702 USA
[6] NCI Frederick, SAIC Frederick, Lab Antiviral Drug Mechanisms, Frederick, MD 21702 USA
[7] Univ N Carolina, Dept Microbiol & Immunol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[8] NCI Frederick, Nat Prod Branch, Frederick, MD 21702 USA
关键词
Kaposi's sarcoma associated hetpesvirus; natural products; reactivation;
D O I
10.1002/ijc.22205
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Kaposi's sarcoma (KS) and its causative agent, Kaposi's sarcoma associated herpesvirus (KSHV/HHV-8), a gamma2 herpesvirus, have distinctive geographical distributions that are largely unexplained. We propose the "oncoweed" hypothesis to explain these differences, namely that environmental cofactors present in KS endemic regions cause frequent reactivation of KSHV in infected subjects, leading to increased viral shedding and transmission leading to increased prevalence of KSHV infection as well as high viral load levels and antibody titers. Reactivation also plays a role in the pathogenesis of KSHV-associated malignancies. To test this hypothesis, we employed an in vitro KSHV reactivation assay that measured increases in KSHV viral load in KSHV infected primary effusion lymphoma (PEL) cells and screened aqueous natural product extracts from KS endemic regions. Of 4,842 extracts from 38 countries, 184 (5%) caused KSHV reactivation. Extracts that caused reactivation came from a wide variety of plant families, and extracts from Africa, where KSHV is highly prevalent, caused the greatest level of reactivation. Time course experiments were performed using 28 extracts that caused the highest levels of reactivation. The specificity of the effects on viral replication was examined using transcriptional profiling of all viral mRNAs. The array data indicated that the natural extracts caused an ordered cascade of lytic replication similar to that seen after induction with synthetic activators. These in vitro data provide support for the "oncoweed" hypothesis by demonstrating basic biological plausibility. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:321 / 328
页数:8
相关论文
共 50 条
  • [1] Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma
    Gruffat, H
    Sergeant, A
    Manet, E
    MICROBES AND INFECTION, 2000, 2 (06) : 671 - 680
  • [2] Kaposi's sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic Kaposi's sarcoma
    Pellet, Claire
    Kerob, Delphine
    Dupuy, Alain
    Carmagnat, Mary V.
    Mourah, Samia
    Podgorniak, Marie-Pierre
    Toledano, Cecile
    Morel, Patrice
    Verola, Olivier
    Dosquet, Christine
    Hamel, Yamina
    Calvo, Fabien
    Rabian, Claire
    Lebbe, Celeste
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (03) : 621 - 627
  • [3] Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa
    Chang, Y
    Ziegler, J
    Wabinga, H
    KatangoleMbidde, E
    Boshoff, C
    Schulz, T
    Whitby, D
    Maddalena, D
    Jaffe, HW
    Weiss, RA
    Moore, PS
    Mugerwa, JW
    Katabira, E
    Mwidu, S
    Beral, V
    Newton, R
    Parkin, M
    DeCock, K
    ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (02) : 202 - 204
  • [4] Angiogenesis,Kaposi’s Sarcoma and Kaposi’s Sarcoma-associated Herpesvirus
    Tao KANG1
    2. Graduate School of the Chinese Academy of Sciences
    3. Tumor Virology Program
    Virologica Sinica, 2008, (06) : 449 - 458
  • [5] Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus
    Dittmer, Dirk P.
    Krown, Susan E.
    CURRENT OPINION IN ONCOLOGY, 2007, 19 (05) : 452 - 457
  • [6] Kaposi's sarcoma-associated herpesvirus infection and Kaposi's sarcoma in Brazil
    Ramos-da-Silva, S.
    Eigui-de-Oliveira, D.
    Borges, L.
    Bacchi, C. E.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2006, 39 (05) : 573 - 580
  • [7] Kaposi's sarcoma-associated herpesvirus
    Boshoff, C
    Weiss, RA
    ADVANCES IN CANCER RESEARCH, VOL 75, 1998, 75 : 57 - 86
  • [8] Kaposi's sarcoma-associated herpesvirus
    Boshoff, C
    Weiss, RA
    CURRENT OPINION IN INFECTIOUS DISEASES, 1997, 10 (01) : 26 - 31
  • [9] Mechanisms of Kaposi's Sarcoma-Associated Herpesvirus Latency and Reactivation
    Ye, Fengchun
    Lei, Xiufen
    Gao, Shou-Jiang
    ADVANCES IN VIROLOGY, 2011, 2011
  • [10] Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma
    Moore, PS
    Kingsley, LA
    Holmberg, SD
    Spira, T
    Gupta, P
    Hoover, DR
    Parry, JP
    Conley, LJ
    Jaffe, HW
    Chang, Y
    AIDS, 1996, 10 (02) : 175 - 180